Quantitative ligandomics for systematic identification of therapeutic ligands
The present invention is directed to methods for developing novel anti-angiogenic therapies. This invention discovers secretogranin III (Scg3) not only as a novel disease-selective angiogenic factor but also as a target for anti-angiogenic therapy of vascular diseases. Inhibitors against Scg3 can treat diabetic retinopathy, wet age-related macular degeneration, retinopathy of prematurity, retinal vein occlusion, neovascular glaucoma, corneal neovascularization, and cancers.
A C C C A C G A G A G C C C C C C A C A C C G C C
A61P C12Q C12N C07K A61P C12Q G01N A61K G01N A61K G01N C07K C07K C07K C07K C07K C12N A61P C07K A61P C12N C12N G01N C12N C07K
inventional inventional inventional additional inventional inventional inventional additional inventional inventional additional additional inventional additional additional additional inventional inventional additional inventional additional additional inventional additional inventional
Wei
Li